NOVO.B.DK

308

+0.77%↑

HLUNB.DK

39.18

+2.57%↑

AMBUB.DK

83.1

+0.73%↑

NOVO.B.DK

308

+0.77%↑

HLUNB.DK

39.18

+2.57%↑

AMBUB.DK

83.1

+0.73%↑

NOVO.B.DK

308

+0.77%↑

HLUNB.DK

39.18

+2.57%↑

AMBUB.DK

83.1

+0.73%↑

NOVO.B.DK

308

+0.77%↑

HLUNB.DK

39.18

+2.57%↑

AMBUB.DK

83.1

+0.73%↑

NOVO.B.DK

308

+0.77%↑

HLUNB.DK

39.18

+2.57%↑

AMBUB.DK

83.1

+0.73%↑

Search

Coloplast A-S (Class B)

Fermé

495.6 1.37

Résumé

Variation du prix de l'action

24h

Actuel

Min

485.8

Max

497.7

Chiffres clés

By Trading Economics

Revenu

522M

1.4B

Ventes

83M

7B

P/E

Moyenne du Secteur

27.294

121.746

BPA

6.32

Rendement du dividende

4.78

Marge bénéficiaire

19.835

Employés

16,983

EBITDA

309M

2.3B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+11.86% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

4.78%

2.26%

Prochains Résultats

12 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-9.7B

109B

Ouverture précédente

494.23

Clôture précédente

495.6

Coloplast A-S (Class B) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 févr. 2026, 23:57 UTC

Actions en Tendance

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

12 févr. 2026, 23:35 UTC

Résultats
Principaux Mouvements du Marché

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

12 févr. 2026, 23:28 UTC

Résultats

Applied Materials Profit Rises on Soaring AI Demand -- Update

12 févr. 2026, 21:47 UTC

Résultats

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

13 févr. 2026, 00:00 UTC

Market Talk

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

12 févr. 2026, 23:47 UTC

Market Talk

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

12 févr. 2026, 23:38 UTC

Market Talk

Gold Steady; Could Undergo Technical Recovery -- Market Talk

12 févr. 2026, 23:33 UTC

Résultats

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

12 févr. 2026, 23:09 UTC

Market Talk

South32's Hermosa Review Stokes Spending Fears -- Market Talk

12 févr. 2026, 22:55 UTC

Résultats
Actions en Tendance

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

12 févr. 2026, 22:46 UTC

Market Talk

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

12 févr. 2026, 22:23 UTC

Résultats

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

12 févr. 2026, 22:15 UTC

Résultats

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

12 févr. 2026, 22:15 UTC

Résultats

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

12 févr. 2026, 22:15 UTC

Résultats

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

12 févr. 2026, 22:15 UTC

Résultats

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

12 févr. 2026, 22:00 UTC

Résultats

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12 févr. 2026, 22:00 UTC

Résultats

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

12 févr. 2026, 22:00 UTC

Résultats

Agnico-Eagle Mines 4Q Net $1.52B >AEM

12 févr. 2026, 22:00 UTC

Résultats

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

12 févr. 2026, 22:00 UTC

Résultats

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12 févr. 2026, 22:00 UTC

Résultats

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

12 févr. 2026, 21:57 UTC

Résultats

XP 4Q Rev BRL4.95B >XP

12 févr. 2026, 21:52 UTC

Résultats

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 févr. 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

12 févr. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12 févr. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 févr. 2026, 21:47 UTC

Résultats

Morningstar 4Q Rev $641M >MORN

12 févr. 2026, 21:39 UTC

Résultats

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 févr. 2026, 21:38 UTC

Résultats

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Comparaison

Variation de prix

Coloplast A-S (Class B) prévision

Objectif de Prix

By TipRanks

11.86% hausse

Prévisions sur 12 Mois

Moyen 901.38 DKK  11.86%

Haut 1,056 DKK

Bas 720 DKK

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

8 ratings

2

Achat

4

Maintien

2

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat